TerminatedPhase 3

Extension Study Of Tanezumab In Osteoarthritis

Stopped: See termination reason in detailed description.

United States2,147 participantsStarted 2009-02-06

Plain-language summary

Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must have participated in previous (specific) Phase 3 trials of Tanezumab in osteoarthritis Exclusion Criteria: * Willing to comply with scheduled visits and treatment plan Is medically fit to participate in the trial in the judgement of the Investigator

What they're measuring

Number of Participants With Treatment Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)

Timeframe: A4091016: Baseline (Day 1) up to 112 days after last dose of study medication (up to Week 80)

Number of Participants With Abnormal Laboratory Findings

Timeframe: A4091016: Day 1 up to Week 80

Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings

Timeframe: A4091016: Baseline (Day 1) up to Week 80

Trial details

NCT IDNCT00809783

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-11-02

Results submitted2021-01-29

View on ClinicalTrials.gov More Osteoarthritis trials